A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)	Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L2, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 3	2026-04-30		NCT06051409

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ascentage Pharma Group Inc.	30
Guangzhou Healthquest Pharma Co., Ltd	2

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Alfred Health	Melbourne	Australia	32
Guangdong Province People's Hospital	Guangdong	China	1
Henan Cancer Hospital	Zhengzhou	China	57
Institute of Blood Transfusion of Chinese Academy of Medical Sciences	Tianjin	China	2
Nanfang Hospital of Southern Medical University	Guangdong	China	1
Royal Adelaide Hospital	Adelaide	Australia	132
Royal North Shore Hospital	St Leonards	Australia	2
Royal Perth Hospital	Perth	Australia	2
Shanghai Jiao Tong University School of Medicine Ruijin Hospital	Shanghai	China	1
The First Affiliated Hospital of Bengbu Medical School	Bengbu	China	1
The First Affiliated Hospital of Suzhou University	Suzhou	China	1
West China Hospital of Sichuan University	Chengdu	China	17
Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology	Wuhan	China	1
Xinqiao Hospital of Army Medical University	Chongqing	China	1